Janakiraman Subramanian, MD, discusses the potential utility of dostarlimab in previously treated patients with non–small cell lung cancer.
Janakiraman Subramanian, MD, medical oncologist, director of Thoracic Oncology, Center for Precision Medicine, Saint Luke’s Cancer Institute, discusses the potential utility of dostarlimab in previously treated patients with non–small cell lung cancer (NSCLC).
During the 2020 ESMO Virtual Congress, initial findings from the NSCLC expansion cohort of the ongoing phase 1 GARNET trial were presented. The results demonstrated that dostarlimab was safe, well tolerated, and effective in patients with previously treated advanced or recurrent NSCLC, Subramanian says.
Regarding administration, patients received 500 mg of dostarlimab every 3 weeks for cycles 1 to 4, then 1000 mg of dostarlimab every 6 weeks until disease progression, Subramanian explains.
Notably, as institutions continue to limit the number of patient visits during the coronavirus disease 2019 pandemic, this dosing approach could be especially beneficial for patients, Subramanian adds.
As the GARNET trial continues to evaluate dostarlimab in patients with advanced solid tumors, the field is hopeful that the PD-1 antibody will continue to demonstrate antitumor effects for patients with NSCLC, Subramanian concludes.